AroCell has announced that the patent regarding the method of determining a likelihood of cancer relapse is now granted by United States Patent and Trademark Office.
The patent claims the method of determining a likelihood of cancer relapse in a subject who has completed cancer tumour surgery, radiotherapy treatment and/or chemotherapy treatment comprises contacting an antibody that binds specifically to a serum form of Thymidine kinase 1 (STK1) protein with a blood serum sample one to six months after completing the surgery and/or treatment, and before any cancer relapse has been detected.
“We are delighted that the U.S. Patent and Trademark Office has granted this patent. This reinforce our patent position in the U.S. and increases AroCell’s attractiveness as a business partner. We will continue to develop our portfolio of proprietary assets to further expand its business opportunities and to support our product AroCell TK 210 ELISA,” says Michael Brobjer, CEO AroCell.